Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer -: A systematic review

被引:24
作者
Akl, Elie A. [1 ]
Rohilla, Sandeep [2 ]
Barba, Maddalena [3 ]
Sperati, Francesca [3 ]
Terrenato, Irene [3 ]
Muti, Paola [3 ]
Bdair, Fadi [1 ]
Schuenemann, Holger J. [3 ,4 ]
机构
[1] SUNY Buffalo, Dept Med, Buffalo, NY 14215 USA
[2] Univ Delhi, Maulana Azad Med Coll, Dept Med, Delhi 110007, India
[3] Italian Natl Canc Inst Regina Elena, Dept Epidemiol, Rome, Italy
[4] McMaster Univ, Dept Clin Epidemiol & Biostat, Clin Adv Res & Informat Translat Res Grp, Hamilton, ON, Canada
关键词
cancer; low-molecular-weight heparin; unfractionated heparin; venous thromboembolism;
D O I
10.1002/cncr.23814
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The authors compared the relative efficacy and safety of low-molecuar-weight heparin (LMWH) and Unfractionated heparin (UFH) for the initial treatment of venous thromboembolism (VTE) between patients with and without cancer. METHODS. By using Cochrane methodology for systematic reviews, separate meta-analyses were conducted for Subgroups of patients with and without cancer, and relative risks (RRs) were compared for statistical significance. The methodologic quality for each Outcome was assessed by using the Grading of Recommendations Assessment, Development, and Evaluation approach. RESULTS. LMWH reduced mortality significantly compared with UFH in patients with cancer (RR of 0.71; 95% confidence interval [95% CI], 0.52-0.98 [moderate-quality evidence]) but not in patients without cancer (RR of 0.97; 95% CI, 0.651.46 [low-quality evidence]). However, the difference in the RR for the 2 subgroups did not reach statistical significance (P = .113). The difference between LMWH and UFH in the effect on recurrent VTE was not statistically significant in the subgroup with cancer (RR of 0.78; 95% CI, 0.29-2.08 [low-quality evidence]), in the subgroup Without cancer (RR of 0.94; 95% CI, 0.60-1.46 [low-quality evidence]), or between the 2 subgroups (P =.367). No data were available for bleeding outcomes, thrombocytopenia, or postphlebitic syndrome. CONCLUSIONS. The Current results indicated that LMWH most likely is superior to UFH in reducing mortality in the initial treatment of VTE for patients with cancer. There is a need for more and better designed trials to confirm these findings.
引用
收藏
页码:1685 / 1694
页数:10
相关论文
共 46 条
[21]   SUBCUTANEOUS LOW-MOLECULAR-WEIGHT HEPARIN COMPARED WITH CONTINUOUS INTRAVENOUS HEPARIN IN THE TREATMENT OF PROXIMAL-VEIN THROMBOSIS [J].
HULL, RD ;
RASKOB, GE ;
PINEO, GF ;
GREEN, D ;
TROWBRIDGE, AA ;
ELLIOTT, CG ;
LERNER, RG ;
HALL, J ;
SPARLING, T ;
BRETTELL, HR ;
NORTON, J ;
CARTER, CJ ;
GEORGE, R ;
MERLI, G ;
WARD, J ;
MAYO, W ;
ROSENBLOOM, D ;
BRANT, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (15) :975-982
[22]   Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio:: A retrospective analysis [J].
Hutten, BA ;
Prins, MH ;
Gent, M ;
Ginsberg, J ;
Tijssen, JGP ;
Büller, HR .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3078-3083
[23]   Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants [J].
Iorio, A ;
Guercini, F ;
Pini, M .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (09) :1906-1913
[24]  
Kakkar AK, 2000, BLOOD, V96, p449A
[25]   Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home [J].
Koopman, MMW ;
Prandoni, P ;
Piovella, F ;
Ockelford, PA ;
Brandjes, DPM ;
vanderMeer, J ;
Gallus, AS ;
Simonneau, G ;
Chesterman, CH ;
Prins, MH ;
Bossuyt, PMM ;
deHaes, H ;
vandenBelt, AGM ;
Sagnard, L ;
DAzemar, P ;
Buller, HR .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (11) :682-687
[26]  
Koopman MMW, 1997, NEW ENGL J MED, V337, P1251
[27]   A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis [J].
Levine, M ;
Gent, M ;
Hirsh, J ;
Leclerc, J ;
Anderson, D ;
Weitz, J ;
Ginsberg, J ;
Turpie, AG ;
Demers, C ;
Kovacs, M ;
Geerts, W ;
Kassis, J ;
Desjardins, L ;
Cusson, J ;
Cruickshank, M ;
Powers, P ;
Brien, W ;
Haley, S ;
Willan, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (11) :677-681
[28]  
LINDMARKER P, 1994, THROMB HAEMOSTASIS, V72, P186
[29]  
LOPACIUK S, 1992, THROMB HAEMOSTASIS, V68, P14
[30]   A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis [J].
Luomanmaki, K ;
Grankvist, S ;
Hallert, C ;
Jauro, I ;
Ketola, K ;
Kim, HC ;
Kiviniemi, H ;
Koskivirta, H ;
Sorskog, L ;
Vilkko, P .
JOURNAL OF INTERNAL MEDICINE, 1996, 240 (02) :85-92